论文部分内容阅读
亚细胞层面尤其是基因层面的分子医学研究就是希望通过识别能够用于更加精确的药理学攻击的目标,以实现在药物治疗上的真正突破。对于抗癌药物吉非替尼,研究界对该药感到满意,而临床医生和病人却对此药有些失望。在本专栏去年年初首次接触吉非替尼时[Science Watch,16(1):5,January／February 2005],对非小细胞类型肺癌(NSCLC)患者的临床试验开始出现。对表皮生
Molecular medical research at the cellular level, and especially at the genetic level, is a real hope to achieve a real breakthrough in medical treatment by identifying the targets that can be used for more precise pharmacological attacks. For the anticancer drug gefitinib, the research community is satisfied with the drug, but clinicians and patients are disappointed with the drug. In the first column of this collateral exposure to gefitinib early last year [Science Watch, 16 (1): 5, January / February 2005] clinical trials of patients with non-small cell lung cancer (NSCLC) began to occur. On the epidermis